Seneca Biopharma, Inc. Announces Completion of Phase II Clinical Study in China for the Treatment of Ischemic Stroke

Rhea-AI Summary

Seneca Biopharma, Inc. (Nasdaq: SNCA) has announced the completion of its non-GCP Phase II study evaluating NSI-566 for chronic ischemic stroke treatment in Beijing, China. With the last subject's final follow-up assessment finished, the company is set to release top-line data in Q4 2020. Chronic ischemic stroke, affecting millions globally, currently has no effective interventional therapies, highlighting the significance of this study. The company focuses on developing innovative treatments for high unmet medical needs while transforming through new science and technology acquisitions.

Positive

• Completion of non-GCP Phase II study for NSI-566 in chronic ischemic stroke.
• Top-line data expected in Q4 2020, indicating progress towards potential treatment.

Negative

• None.

GERMANTOWN, Md., Sept. 10, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today announced that the last subject completed their final follow-up assessment in the Company's non-GCP Phase II study in Beijing, China evaluating NSI-566 for the treatment of chronic ischemic stroke. With this milestone achieved, the company remains on schedule to release top line data for the study during the fourth quarter of 2020.

About Seneca Biopharma, Inc.

Seneca Biopharma, Inc., is a clinical-stage biopharmaceutical company developing novel treatments for diseases of high unmet medical need. The Company is in the process of transforming the organization through the acquisition or in-licensing of new science and technologies, to develop with the goal of providing meaningful therapies for patients.

About Ischemic Stroke

Ischemic stroke, the most common type of stroke, occurs as a result of an obstruction within a blood vessel supplying blood to the brain. Approximately 15 million people worldwide suffer stroke each year, of which approximately 87% are ischemic strokes. Post-stroke motor deficits include paralysis in arms and legs and can be permanent. No interventional therapy exists for chronic stroke and treatment is focused on rehabilitation, but only a small fraction of survivors achieves complete functional recovery.

Cautionary Statement Regarding Forward Looking Information:

This news release contains "forward-looking statements" made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "seek" or "will." Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Seneca's periodic reports filed with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Reports on Form 10-Q as well as and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.

View original content:http://www.prnewswire.com/news-releases/seneca-biopharma-inc-announces-completion-of-phase-ii-clinical-study-in-china-for-the-treatment-of-ischemic-stroke-301126905.html

SOURCE Seneca Biopharma, Inc.

FAQ

What is the purpose of Seneca Biopharma's NSI-566 Phase II study?

The study aims to evaluate NSI-566 as a potential treatment for chronic ischemic stroke, a condition with high unmet medical need.

When will the results of the NSI-566 study be released?

Top-line data from the Phase II study is expected to be released in the fourth quarter of 2020.

How common is chronic ischemic stroke?

Chronic ischemic stroke accounts for about 87% of the 15 million strokes occurring worldwide each year.

What are the potential implications of the Phase II study results for SNCA stock?

Successful results could positively impact SNCA's stock by attracting investor interest and enhancing the company's market position in stroke treatment.